ArticleNature reviews. Clinical oncology2018
Low-value approvals and high prices might incentivize ineffective drug development.
Article in Nature reviews. Clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- The impact of the United States most favored nation policies on prices of branded medicines and research and development.Health policy OPEN · 2026Review
- An analysis of US net cancer drug launch prices and clinical efficacy and certainty of evidence from 2008 to 2022.Health affairs scholar · 2025Article
- The value of anticancer drugs - a regulatory view.Nature reviews. Clinical oncology · 2022Review
- Peptide-Based Drug Delivery Systems.Medicina (Kaunas, Lithuania) · 2021Review
- Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations.Journal of experimental & clinical cancer research : CR · 2021Review
- Early-Phase Clinical Trials and Reimbursement Submissions to the Pan-Canadian Oncology Drug Review.PharmacoEconomics · 2021Article
- Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018.JAMA internal medicine · 2021Article
- Whose shoulders is health research standing on? Determining the key actors and contents of the prevailing biomedical research agenda.PloS one · 2021Article
- Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study.BMJ (Clinical research ed.) · 2020Article
- ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors.Theranostics · 2020Article
- Patients with FLT3-mutant AML needed to enroll on FLT3-targeted therapeutic clinical trials.Blood advances · 2019Article
- Association of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival: A Pooled Analysis.JAMA network open · 2019Review
- Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies.JAMA network open · 2019Article
- To all involved - we have a problem.Nature reviews. Clinical oncology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
29760505What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.